India, Nov. 5 -- Ironwood Pharmaceuticals, Inc. (IRWD), reported higher third-quarter 2026 revenue and net income, driven by growth in LINZESS collaboration revenue and improved operating performance. The company raised its full-year 2026 financial guidance for the second consecutive quarter.
Company Profile:
Ironwood Pharmaceuticals is a healthcare company focused on developing and commercializing therapies for gastrointestinal diseases. Its marketed product portfolio includes LINZESS (linaclotide), which is commercialized in collaboration with AbbVie in the U.S.
Q3 Financial Results:
Total revenue increased 8.9% to $133.0 million from $122.1 million in the third quarter of 2025.
LINZESS collaboration revenue rose 8.6% to $129.9 milli...